###### Key questions

What is already known about this subject?
=========================================

-   Early reviews indicate that exercise training may improve brain natriuretic peptide (BNP) and amino (N) portion of BNP (NT-proBNP) in patients with heart failure (HF).

-   A number of new trials have compared different types of conventional and non-conventional modes of training on BNP and NT-proBNP, but the optimal exercise prescription for reducing HF biomarkers is unknown.

What does this study add?
=========================

-   The review updates the evidence in regard to the effect of exercise training on the established HF biomarkers, BNP and NT-proBNP.

-   Additionally, the response of a number of emerging biomarkers to exercise training has been investigated in patients with HF.

-   The pooled analysis of conventional exercise training confirms improvements in BNP and NT-proBNP but demonstrates only limited evidence for non-conventional training.

-   Exercise training may also improve a number of other biomarkers representative of different pathophysiological pathways involved in HF progression.

How might this impact on clinical practice?
===========================================

-   The exercise prescription for patients with HF can be optimised to improve biomarker profile and hence prognosis, providing a valuable resource for both clinicians and patients.

Introduction {#s1}
============

Heart failure (HF) is a complex syndrome resulting from multiple conditions and underlying disorders and continues to be a significant burden on the healthcare system. Over the past three decades, an increasing number of studies have provided evidence on a range of benefits of exercise training in patients with HF.[@R1] In patients with stable HF, exercise training is now a Class 1 recommendation in HF guidelines.[@R6]

Numerous pathways are involved in the development and progression of HF, and the discovery of biomarkers has and will hopefully continue to enhance our understanding of the pathophysiology.[@R8] Circulating biomarkers are important in the diagnosis, risk stratification and management of patients with HF.[@R6] HF biomarkers tend to be classified according to the associated pathophysiological processes.[@R12] These include biomarkers of myocardial stretch, myocyte injury, fibrosis, matrix remodelling, inflammation, oxidative stress, neurohumoral activation and renal dysfunction.[@R10] Some biomarkers may bridge several pathophysiological processes. Currently, brain (B-type) natriuretic peptide (BNP) and its more stable inert form, the amino (N terminal) portion (NT-proBNP), markers of myocardial stretch, are recognised as the gold standard diagnostic and prognostic biomarkers in HF.[@R6]

Over recent decades, the role of circulating biomarkers in HF has evolved, with the emergence of a number of novel biomarkers.[@R12] Among these biomarkers, suppression of tumorigenicity 2 (ST2) and galectin-3 (Gal-3) have demonstrated prognostic value in HF,[@R14] and both are shown to be predictors of sudden cardiac death.[@R18] In fact, the combination of the gold standard cardiac biomarkers of BNP/NT-proBNP with the newer biomarkers, such as soluble ST2 (sST2) and Gal-3, may improve risk stratification and prognosis.[@R10] Other emerging biomarkers, mid-regional atrial natriuretic peptide (MR-proANP), mid-regional adrenomedullin (MR-proADM) and copeptin (CT-proAVP), have also been shown to have prognostic value in HF.[@R9]

In addition to their diagnostic and prognostic utility, biomarker profiles may prove beneficial in guiding HF therapy and improving treatment strategies,[@R10] including the identification of patients with HF that may respond to exercise training.[@R21] A 2010 meta-analysis[@R24] suggested that exercise training had a favourable effect on both BNP and NT-proBNP. The results of which were confirmed by a 2011 individual patient data (IPD) meta-analysis, with a 37.4% and 28.3% reduction in NT-proBNP and BNP, respectively.[@R25] Furthermore, BNP and NT-proBNP changes are correlated with changes in peak oxygen consumption (VO~2peak~).[@R25]

The aim of this systematic review and meta-analysis was first to update the previous reviews as a number of additional studies have investigated BNP and/or NT-proBNP after training interventions. Second, given the emergence of new biomarkers in HF trials, we intended to add to the current literature the inclusion of a selected number of emerging biomarkers. Furthermore, differing to previous analyses, we expanded our review to include additional modalities of exercise therapy due to their increasing utilisation in cardiac rehabilitation programmes and trials, which may provide alternatives for subgroups of patients with HF.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

Potential studies were identified by conducting systematic searches of PubMed, EMBASE, CINHAL and the Cochrane Library of Controlled Trials up until 31 October 2017. Searches included a mix of MeSH and free-text terms related to the key concepts of HF, exercise training and biomarkers. Additionally, systematic reviews, meta-analyses and reference lists of papers were hand searched for additional studies. One reviewer (MJP) conducted the search, and full articles were assessed for eligibility by two reviewers (MJP and NAS). A sample search strategy is presented in online [supplementary files](#SP1){ref-type="supplementary-material"}. Additional information was requested from five authors, with three responses.
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Study selection {#s2b}
---------------

### Study type and participants {#s2b1}

Randomised controlled trials (RCTs) and controlled trials of exercise therapy in patients with HF aged 18 years or older were included. HF type (ie, preserved, moderately reduced and reduced ejection fraction) was not considered as an inclusion or exclusion criteria. Only studies in which the authors specifically reported a patient diagnosis of HF were included. Studies assessing intervention effect on acute or decompensated HF were excluded.

### Intervention {#s2b2}

Exercise therapy included both conventional training, defined as aerobic training (AT), resistance training (RT) and combined AT and RT, and non-conventional modes of therapy, defined as Yoga, Tai Chi, stretching and the physical therapies of functional electrical stimulation (FES) and inspiratory muscle training (IMT). Studies must have compared an exercise intervention to a usual care or education control group, with no formally prescribed exercise, and the duration of the exercise training must have been for a minimum of 4 weeks. Studies in which the participants had participated within a formal exercise rehabilitation programme within the last 6 months were excluded.

### Outcomes {#s2b3}

Studies were eligible to be included in the review if they reported one or more of the following outcomes in serum or plasma: BNP, NT-proBNP, cardiac troponin (cTnT), sST2, Gal-3, MR-proANP, MR-proADM and CT-proAVP.

### Exclusions {#s2b4}

Abstracts and non-English studies were excluded.

#### Data extraction {#s2b4a}

One reviewer (MJP) extracted the data. For each study, the following information was extracted: (1) author, year of publication and study design, (2) demographic and clinical characteristics, (3) exercise intervention characteristics, (4) mean, SD, P value and main findings in regard to biomarkers and (5) details of assessment methodology for biomarkers.

#### Data synthesis {#s2b4b}

Statistical analyses were performed using Revman V.5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark). Individual meta-analyses were completed for continuous data by using the change in the mean and SD. Where the change in mean and SD was not reported, the change in mean was calculated by subtracting the preintervention mean from the postintervention mean, and Revman V.5.3 enabled calculations of SD using number of participants in each group, within or between group p values or 95% CI. Where p values were not provided, the SD of the mean difference (MD) was calculated using the formula: SD=square root \[(SD~pretreatment~)^2^+(SD~post-treatment~)^2^−(2 r ×SD~pretreatment~×SD~post-treatment~)\], assuming a correlation coefficient (r)=0.5, which is considered a conservative estimate.[@R26] Where data were not presented in text or tables and authors could not be reached, data presented in figures or reported in prior meta-analyses were extracted or accessed where possible.

Data were pooled for meta-analysis when two or more studies measured the same outcome and provided data in a format suitable for pooling. Where a study included multiple intervention groups and data were not provided for the combined intervention, data were entered separately for each group, and the sample size of the control group was divided by the number of intervention groups to eliminate overinflation of the sample size. A random-effects inverse variance was used with the effects to measure MD. We used a 5% level of significance and a 95% CI to report change in outcome measures. Both BNP and NT-proBNP are commonly reported in SI units (pmol/L) or conventional units (pg/mL). Owing to large values associated with NT-proBNP, change data were converted from pg/mL to pmol/L for both NT-proBNP and BNP for presentation. Data were converted using the following factors: for NT-proBNP pmol/L=pg/mL ×0.118 and BNP pmol/L=pg/mL ×0.289.

For meta-analysis, we did not pool studies in which participants were clearly identified as only having heart failure with preserved ejection fraction (HFpEF), with other studies. We grouped studies for analysis according to conventional or non-conventional training modalities. For studies where the mean or SD of outcomes was not reported, but median, IQR or median and range were reported or where only a descriptive result was reported in regard to postintervention changes, a table and descriptive analysis are used.

**Sensitivity analysis:** In order to evaluate the influence of each study on the overall effect size, sensitivity analysis using the leave-one-out approach was conducted. Where SD was imputed, additional analyses were also carried out with different values for the correlation coefficient (r=0.75 and 0.25) to determine whether the overall results of the analyses were robust to the use of imputed correlation coefficients.

#### Heterogeneity and publication bias {#s2b4c}

Heterogeneity was quantified using the I^2^ test.[@R27] Values range from 0% (homogeneity) to 100% (high heterogeneity).[@R27] Visual inspection of funnel plots[@R28] assessed risk of publication bias.

#### Study quality {#s2b4d}

Study quality was assessed using the Tool for the Assessment of Study Quality and Reporting in Exercise (TESTEX)[@R29] by two authors (MJP and NK). In case of discrepancies, a third author (NAS) was consulted.

Results {#s3}
=======

The initial search generated a total of 3419 articles. After removal of duplicates and exclusion of articles based on abstract and title, 77 full-text articles remained for screening. Full screening resulted in 43 articles meeting the stated inclusion criteria ([figure 1](#F1){ref-type="fig"}, Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement), of which 27 studies were included in meta-analyses. Details of full-text articles reviewed but excluded are provided, with reasons, in online [supplementary table S1](#SP1){ref-type="supplementary-material"}.

![PRISMA flow diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](openhrt-2018-000819f01){#F1}

Study and participant characteristics {#s3a}
-------------------------------------

A general description of included studies is provided in [table 1](#T1){ref-type="table"}. Of the 43 included studies, two[@R30] studies were from the same trial but provided different biomarker information, and two[@R32] studies contained an overlap of some participants, and data were combined into one dataset for meta-analysis to eliminate data overlap. Four[@R22] of the studies were controlled but not randomised, one[@R37] study randomised

###### 

Overview of studies included in the review

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                  Design                      Participant characteristics                                    Intervention
  -------------------------------------- --------------------------- -------------------------------------------------------------- --------------------------------------------
  Ahmad *et al* [@R53]                   RCT                         n=928 analysed, biomarker substudy HF ACTION Trial\            3 months\
                                                                     E: n=477 (68% male), 59 (51--68) years, LVEF 25% (20--30)\*\   Aerobic
                                                                     C: n=451 (73% male), 59 (51--68) years, LVEF 25% (20--31)\     
                                                                     NYHA Class II--IV (\<1% IV)                                    

  Aksoy *et al* [@R43]                   RCT                         n=57 randomised, n=45 analysed\                                10 weeks\
                                                                     E1: n=15 (87% male), 64±9 years, LVEF 50%±7%\                  Aerobic (E1: IAE, E2: CAE)
                                                                     E2: n=15 (87% male), 60±7 years, LVEF 52%±5%\                  
                                                                     C: n=15 (87% male), 58±11 years, LVEF 52%±6%\                  
                                                                     NYHA Class II--III                                             

  Antonicelli *et al* [@R44]             RCT                         n=343 randomised, n=313 completed 6 months\                    6 months\
                                                                     E: n=170 (61% male), 76±5 years, LVEF 48%±13%\                 Aerobic
                                                                     C: n=173 (53% male), 78±6 years, LVEF 49%±13%\                 
                                                                     NYHA Class ≥2                                                  

  Van Berendoncks *et al* [@R34]         Non-RCT\                    n=80 analysed\                                                 4 months\
                                         Cohort with control group   E: n=46 (70% male), 58±10 years, LVEF 17% (14--22)\*\          Aerobic and combined
                                                                     C: n=34 (59% male), 61±12 years, LVEF 19% (15--24)\            
                                                                     NYHA Class II--III                                             

  Billebeau *et al* [@R22]               Non-RCT\                    n=131 enrolled\                                                4--6 months\
                                         Cohort with control group   E: n=107 (86% male), 59 (52--66) years, LVEF 30% (25--39)\*\   Aerobic
                                                                     C: n=24 (79% male), 63 (53--72) years, LVEF 35% (30--40)\      
                                                                     NYHA Class II--IV                                              

  Brubaker *et al* [@R65]                RCT                         n=59 randomised, n=44 analysed\                                16 weeks\
                                                                     E: n=30 (63% male), 70±5 years, LVEF 32%±9%\                   Aerobic
                                                                     C: n=29 (69% male), 70±6 years, LVEF 30%±9%\                   
                                                                     NYHA Class II--IV (n=1 Class IV)                               

  Butterfield *et al* [@R58]             RCT                         n=19 randomised, n=17 analysed\                                12 weeks\
                                                                     E: n=11 (82% male), 66±10 years, LVEF 34%±11%\                 Combined
                                                                     C: n=6 (50% male), 75±12 years, LVEF 35%±14%\                  
                                                                     NYHA Class II--III                                             

  Conraads *et al* [@R48]                RCT                         n=17 randomised and analysed\                                  4 months\
                                                                     E: n=8 (38% male), 57±2 years, LVEF 27%±5%\                    Aerobic
                                                                     C: n=9 (56% male), 61±4 years, LVEF 28%±5%\                    
                                                                     NYHA Class III                                                 

  Conraads *et al*[@R35] (2004)          Non-RCT\                    n=49 enrolled and analysed\                                    4 months\
                                         Cohort with control group   E: n=27 (78% male), 59±2 years, LVEF 26%±1%\                   Combined
                                                                     C: n=22 (68% male), 59±2 years, LVEF 26%±1%\                   
                                                                     NYHA Class II--III                                             

  Delagardelle *et al* [@R37]            RCT/non-RCT†                n=60 randomised and analysed\                                  \~13.3 weeks Combined, aerobic or strength
                                                                     E: n=45 (84% male), 59±6 years, LVEF 24%±5%\                   
                                                                     C: n=15 (87% male), 56±8 years, LVEF 25%±6%\                   
                                                                     NYHA Class II                                                  

  Edelmann *et al* [@R30]\               RCT                         n=67 randomised, n=64 analysed\                                12 weeks\
  Ex-DHF pilot study                                                 E: n=44 (45% male), 64±8 years, LVEF 68%±7%\                   Combined
                                                                     C: n=20 (40% male), 65±6 years, LVEF 67%±7%\                   
                                                                     NYHA Class II and III                                          

  Eleuteri *et al* [@R54]                RCT                         n=21 randomised and analysed\                                  3 months\
                                                                     E: n=11 (100% male), 66±2 years, LVEF 28%±2%\                  Aerobic
                                                                     C: n=10 (100% male), 63±2 years, LVEF 30%±2%\                  
                                                                     NYHA Class II                                                  

  Fernandes-Silva *et al* [@R23]         RCT                         n=52 randomised, n=40 analysed\                                12 weeks\
                                                                     E: n=28 (50% male), 51±7 years, LVEF 30%±6%\                   Aerobic
                                                                     C: n=16 (62% male), 48±7 years, LVEF 29%±7%\                   
                                                                     NYHA Class I--III                                              

  Fu (2013)[@R57]                        RCT                         n=45 randomised, n=40 analysed\                                12 weeks\
                                                                     E1: n=15 (67% male), 68%±5%, LVEF 38%±4%\                      Aerobic (E1: AIT, E2: MCT)
                                                                     E2: n=15 (60% male), 66±2 years, LVEF 39%±5%\                  
                                                                     C: n=15 (67% male), 68±3 years, LVEF 38%±4%\                   
                                                                     NYHA Class II--III                                             

  Gary *et al* [@R59]                    RCT                         n=24 randomised and analysed\                                  12 weeks\
                                                                     E: n=12 (58% male), 59±11 years, LVEF 23%±8%\                  Combined
                                                                     C: n=12 (42% male), 61±10 years, LVEF 27%±9%\                  
                                                                     NYHA Class II--III                                             

  Guazzi *et al* [@R49]                  RCT                         n=26 randomised and analysed\                                  24 weeks\
                                                                     E: n=18, C: n=8, 68±6 years, LVEF 37%±5%\                      Aerobic
                                                                     NYHA Class II--III                                             

  Jónsdóttir *et al* [@R46]              RCT                         n=51 randomised, n=43 analysed\                                5 months\
                                                                     E: n=21 (76% male), 68±7 years, LVEF 42%±14%\                  Combined
                                                                     C: n=22 (82% male), 69±5 years, LVEF 41%±14%\                  
                                                                     NYHA Class II--III                                             

  Karavidas *et al* [@R66]               RCT                         n=30 randomised and analysed\                                  6 weeks\
                                                                     E: n=20 (80% male), 62±12 years, LVEF 28%±7%\                  FES
                                                                     C: n=10 (80% male), 64±8 years, LVEF 27%±5%\                   
                                                                     NYHA Class II--III                                             

  Karavidas *et al* [@R41]               RCT                         n=30 randomised and analysed\                                  6 weeks\
                                                                     E: n=15 (60% male), 69±9 years, LVEF 64%±8%\                   FES
                                                                     C: n=15 (60% male), 69±8 years, LVEF 63%±5%\                   
                                                                     NYHA Class II--III                                             

  Kato *et al* [@R67]                    RCT                         n=50 randomised and analysed\                                  4 weeks\
                                                                     E: n=25 (80% male), 70±11 years, LVEF 28%±9%\                  Stretching
                                                                     C: n=25 (76% male), 70±8 years, LVEF 29%±9%\                   
                                                                     NYHA Class II--IV                                              

  Kawauchi *et al* [@R68]                RCT                         n=53 randomised, n=35 analysed\                                8 weeks\
                                                                     E1: n=13 (46% male), 54±10 years, LVEF 30%±6%\                 IMT+resistance
                                                                     E2: n=13 (62% male), 56±7 years, LVEF 28%±5%\                  
                                                                     C: n=9 (56% male), 56±7 years, LVEF 29%±7%\                    
                                                                     NYHA Class II--III                                             

  Kitzman *et al* [@R40]                 RCT                         n=53 randomised, n=46 completed\                               16 weeks\
                                                                     E: n=26 (17% male), 70±6 years, LVEF 61%±5%\                   Aerobic
                                                                     C: n=27 (9% male), 69±5 years, LVEF 60%±10%\                   
                                                                     NYHA Class II--III                                             

  Kitzman *et al* [@R39]                 RCT                         n=51 randomised‡\                                              20 weeks\
                                                                     E: n=26 (19% male), 68±6 years, LVEF 61%±6%\                   Aerobic
                                                                     C: n=25 (20% male), 66%±5%, LVEF 63%±6%\                       
                                                                     NYHA Class II--III                                             

  Kobayashi *et al* [@R61]               RCT                         n=28 randomised and analysed\                                  12 weeks\
                                                                     E: n=14 (86% male), 55±2 years, LVEF 29%±2%\                   Aerobic
                                                                     C: n=14 (57% male), 62±2 years, LVEF 33%±2%\                   
                                                                     NYHA Class II and III                                          

  Krishna *et al* [@R45]                 RCT                         n=130 randomised, n=92 analysed\                               12 weeks\
                                                                     E: n=44 (73% male), 49±6 years, LVEF 39%±5%\                   Yoga
                                                                     C: n=48 (67% male), 50±5 years, LVEF 40%±5%\                   
                                                                     NYHA Class I--II                                               

  Malfatto *et al* [@R60]                RCT                         n=54 randomised and analysed\                                  12 weeks\
                                                                     E: n=27 (70% male), 65±11 years, LVEF 31%±6%,\                 Aerobic
                                                                     C: n=27 (74% male), 67±9 years, LVEF 33%±6%,\                  
                                                                     NYHA Class I and II                                            

  Marco *et al* [@R56]                   RCT                         n=22 randomised and analysed\                                  4 weeks\
                                                                     E: n=11 (64% male), 69±9 years, LVEF 38%±16%\                  IMT
                                                                     C: n=11 (91% male), 70±11 years, LVEF 36%±17%\                 
                                                                     NYHA Class II--III                                             

  Meyer *et al* [@R50]                   RCT                         n=42 randomised and analysed\                                  12 weeks\
                                                                     E: n=19 (79% male), 58±10 years, LVEF 29%±13%\                 Aerobic
                                                                     C: n=23 (78% male), 54±9 years, LVEF 30%±11%\                  
                                                                     NYHA Class II--III                                             

  Nilsson *et al* [@R55]                 RCT                         n=78 randomised, n=70 for BNP at follow-up\                    4 months\
                                                                     E: n=39 (77% male), 69±8 years, LVEF 30%±8%\                   Aerobic
                                                                     C: n=39 (79% male), 72±8 years, LVEF 31%±10%\                  
                                                                     NYHA Class II--III                                             

  Nishi *et al* [@R38]                   Retrospective analysis      n=45 randomised, n=31 analysed BNP\                            3 months\
                                                                     E: n=33 (88% male), 51±14 years, LVEF 18%±4%,\                 Aerobic
                                                                     C: n=12 (83% male), 52±16 years, LVEF 18%±5%\                  
                                                                     NYHA Class II--III                                             

  Norman *et al* [@R62]                  RCT                         n=42 randomised, n=39 analysed for BNP\                        24 weeks\
                                                                     E: n=20 (55% male), 56±3 years, LVEF 34%±1%\                   Combined
                                                                     C: n=20 (60% male), 63±3 years, LVEF 32%±1%\                   
                                                                     NYHA Class II--IV                                              

  Palau *et al* [@R42]                   RCT                         n=27 randomised, n=26 analysed\                                12 weeks\
                                                                     E: n=14 (50% male), 68 (60--76) years, LVEF 69% (63--77)\*\    IMT
                                                                     C: n=12 (50% male), 74 (73--77) years, LVEF 76% (68--83)\      
                                                                     NYHA Class II--IV                                              

  Parrinello *et al* [@R63]              RCT                         n=22 randomised and analysed\                                  10 weeks\
                                                                     E: n=11 (73% male), 62±5 years, LVEF 39%±4%\                   Aerobic
                                                                     C: n=11 (64% male), 63±5 years, LVEF 39%±4%\                   
                                                                     NYHA Class II--III                                             

  Passino *et al* [@R32]                 RCT                         n=95 randomised, n=85 analysed\                                9 months\
                                                                     E: n=44 (89% male), 60±2 years, LVEF 35%±2%\                   Aerobic
                                                                     C: n=41 (85% male), 61±2 years, LVEF 32%±2%\                   
                                                                     NYHA Class I--III                                              

  Passino *et al* [@R33]                 RCT                         n=97 randomised, n=90 analysed\                                9 months\
                                                                     E: n=71 (87% male), 61±2 years, LVEF 35%±1%\                   Aerobic
                                                                     C: n=19 (74% male), 63±2 years, LVEF 36%±2%\                   
                                                                     NYHA Class I--III                                              

  Sandri *et al* [@R51]\                 RCT                         n=60 randomised and analysed\                                  4 weeks\
  LEICA Study                                                        E1: n=15 (80% male), 50±5 years, LVEF 27%±1%\                  Aerobic
                                                                     C1: n=15 (87% male), 49±5 years, LVEF 28%±1%\                  
                                                                     E2: n=15 (80% male), 72±4 years, LVEF 29%±2%\                  
                                                                     C2: n=15 (80% male), 72±3 years, LVEF 28%±2%\                  
                                                                     NYHA Class II--III                                             

  Maria Sarullo *et al* [@R52]           RCT                         n=60 randomised and analysed\                                  12 weeks\
                                                                     E: n=30 (77% male), 53±6 years, LVEF 29%±5%\                   Aerobic
                                                                     C: n=30 (74% male), 53±5 years, LVEF 29%±4%\                   
                                                                     NYHA Class II--III                                             

  Stevens *et al* [@R64]                 RCT                         n=28 randomised, n=22 analysed\                                12 weeks\
                                                                     E: n=15 (67% male), 67±3 years, LVEF 39%±3%\                   Combined
                                                                     C: n=7 (86% male), 64±6 years, LVEF 35%±2%\                    
                                                                     NYHA Class I--III                                              

  Trippel *et al* [@R31]\                RCT                         n=67 randomised, n=62 analysed for biomarkers\                 12 weeks\
  Ex-DHF pilot study post hoc analysis                               E: n=44 (45% male), 64±8 years, LVEF 68%±7%\                   Combined
                                                                     C: n=20 (40% male), 65±6 years, LVEF 67%±7%\                   
                                                                     NYHA Class II--III                                             

  Wisløff *et al* [@R47]                 RCT                         n=27 randomised, n=26 analysed\                                12 weeks\
                                                                     E1: n=9 (78% male), 77±9 years, LVEF 28%±7%\                   Aerobic (E1: AIT, E2: MCT)
                                                                     E2: n=9 (78% male), 74±12 years, LVEF 33%±5%\                  
                                                                     C: n=9 (67% male), 76±13 years, LVEF 26%±8%                    

  Yamamoto *et al* [@R36]                Non-RCT\                    n=18 enrolled and analysed\                                    6 months\
                                         Cohort with control group   E: n=10 (90% male), 68 (64--70) years, LVEF 40% (37--43)\*\    Aerobic
                                                                     C: n=8 (100% male), 70 (66--73) years, LVEF 37% (35--38)\      
                                                                     NYHA Class II--III                                             

  Yeh *et al* [@R69]                     RCT                         n=30 randomised and analysed\                                  12 weeks\
                                                                     E: n=15 (67% male), 66±12 years, LVEF 24%±7%\                  Tai Chi
                                                                     C: n=15 (60% male), 61±14 years, LVEF 22%±8%\                  
                                                                     NYHA Class I--IV                                               

  Yeh *et al* [@R70]                     RCT                         n=100 randomised and analysed\                                 12 weeks\
                                                                     E: n=50 (56% male), 68±12 years, LVEF 28%±8%\                  Tai Chi
                                                                     C: n=50 (72% male), 67±12 years, LVEF 30%±7%\                  
                                                                     NYHA Class I--III                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Median (IQR).

†Randomised between three exercise groups, but control group not randomised.

‡Excludes diet and diet and exercise groups.

AIT, aerobic interval training; BNP, brain natriuretic peptide; C, control; CAE, continuous aerobic training; DHF, diastolic heart failure; E, exercise; FES, functional electrical stimulation; IAE, aerobic interval training; IMT, inspiratory muscle training; LVEF, left ventricular ejection fraction; MCT, moderate continuous training; NYHA, New York Heart Association; RCT, randomised controlled trial.

participants between exercise intervention groups, but the control group was not randomised, one[@R38] study was a retrospective analysis and all remaining studies were RCTs. Seven studies,[@R30] representing six trials, included participants with a mean left ventricular ejection fraction (LVEF) \>50%, one[@R43] of which also included participants with LVEF \<50%. Thirty-six trials included participants with mean LVEF \<50%, and the mean LVEF of at least three[@R44] studies indicates the inclusion of participants with a range of ejection fractions, reduced, mid-range and/or preserved ejection fraction. Baseline NT-proBNP and BNP levels are provided in online [supplementary table S2](#SP1){ref-type="supplementary-material"}.

Intervention details {#s3b}
--------------------

A detailed description of the interventions can be found in online [supplementary table S3](#SP1){ref-type="supplementary-material"}. Thirty-four studies used conventional exercise training, eight studies used non-conventional exercise training or therapy and one study combined non-conventional and conventional training. Intervention duration ranged from 4 weeks to 9 months.

Biomarker assessment {#s3c}
--------------------

Biomarker assay details are provided in online [supplementary table S4](#SP1){ref-type="supplementary-material"}.

Outcome measures {#s3d}
----------------

### Amino (N) portion of BNP {#s3d1}

Twenty studies reported on NT-proBNP. Two studies[@R32] contained an overlap of some participants; to avoid possible duplication of data, these studies are represented as one dataset in the meta-analysis.

### Meta-analysis {#s3d2}

Overall, exercise demonstrated a statistically significant improvement in NT-proBNP (pmol/L); MD −47.83 (95% CI −77.23 to −18.43), p=0.001 ([figure 2](#F2){ref-type="fig"}).

![Change (MD) in NT-proBNP (pmol/L) exercise versus control. For conversion to pg/mL=pmol/L divided by 0.118. AIT, aerobic interval training; CAE, continuous aerobic training; IAE, aerobic interval training; IHF, ischaemic heart failure; MCT, moderate continuous training; MD, mean difference; NHF, non-ischaemic heart failure; NT-proBNP, amino (N) portion of BNP.](openhrt-2018-000819f02){#F2}

### Conventional training {#s3d3}

Pooled data from 10 studies[@R32] (14 intervention groups, 315 exercise participants and 212 controls) demonstrated a statistically significant improvement in favour of exercise, on NT-proBNP (pmol/L); MD −32.80 (95% CI −56.19 to −9.42), p=0.006 ([figure 2](#F2){ref-type="fig"}). Removal of the two intervention groups from one[@R43] study, that included patients with a mean ejection fraction of 50%, improved the MD and statistical significance; MD −54.62 (95% CI −74.36 to −34.87) pmol/L, p\<0.00001 (online [supplementary table S5](#SP1){ref-type="supplementary-material"}). Apart from the study by Aksoy *et al*,[@R43], sensitivity analysis using the leave-one-out approach revealed that the results remained relatively stable ([figure 3](#F3){ref-type="fig"}). Sensitivity analyses conducted for different correlation coefficients for SD imputation did not result in any significant variance in overall results.

![Sensitivity analysis NT-proBNP (conventional training) with study removed. AIT, aerobic interval training; CAE, continuous aerobic training; IAE, aerobic interval training; IHF, ischaemic heart failure; MCT, moderate continuous training; NHF, non-ischaemic heart failure; NT-proBNP, amino (N) portion of BNP.](openhrt-2018-000819f03){#F3}

An additional six[@R30] studies ([table 2](#T2){ref-type="table"}) could not be pooled due to differences in data reporting. Five studies presented data as median (IQR) or median (range), and one[@R30] study only included patients with HFpEF. Two studies[@R34] reported preintervention to postintervention NT-proBNP changes in exercise participants, but only one study reported a significant difference compared with control participants.

###### 

Summary of findings of studies for NT-proBNP and BNP not pooled for meta-analysis

  Study                              Design       Intervention           Analysed E/C   Result
  ---------------------------------- ------------ ---------------------- -------------- -----------------------------------------
  NT-proBNP                                                                             
   Conventional training                                                                
    Ahmad *et al* [@R19]             RCT          Aerobic                477/451        ↔ between groups
    Antonicelli *et al* [@R44]       RCT          Aerobic                170/173        ↓ in E and significantly different to C
    Van Berendoncks *et al* [@R34]   Controlled   Aerobic and combined   46/34          ↓ in E, but ↔ for ∆ between E and C
    Edelmann *et al* [@R30]          RCT          Combined               44/20          ↔ in E or C
    Eleuteri *et al* [@R54]          RCT          Aerobic                11/10          ↔ in E or C
    Nilsson *et al* [@R55]           RCT          Aerobic                37/33          ↔ in E or C or between E and C
    Non-conventional                                                                    
    Palau *et al* [@R42]             RCT          IMT                    14/12          ↔ in E or C or between E and C
  BNP                                                                                   
   Conventional training                                                                
    Billebeau *et al* [@R22]         Controlled   Aerobic                107/24         ↓ in E, ↔ in C
    Brubaker *et al* [@R65]          RCT          Aerobic                23/21          ↔ between E and C
    Kitzman *et al* [@R40]           RCT          Aerobic                26/27          ↔ between E and C
    Kitzman *et al* [@R39]           RCT          Aerobic                26/25          ↔ in E or C
    Yamamoto *et al* [@R36]          Controlled   Aerobic                10/8           ↓ in E, ↔ in C
    Non-conventional                                                                    
    Karavidas *et al* [@R41]         RCT          FES                    15/15          ↔ for ∆ between E and C
    Yeh *et al* [@R70]               RCT          Tai Chi                50/50          ↔ for ∆ between E and C

↓ statistically significant, ↔ no statistically significant change.

BNP, brain natriuretic peptide; C, control; E, exercise; FES, functional electrical stimulation; IMT, inspiratory muscle training; NT-proBNP, amino (N) portion of BNP; RCT, randomised controlled trial.

### Non-conventional training {#s3d4}

Pooled data from two[@R45] studies (55 exercise participants and 59 controls) failed to demonstrate a statistically significant improvement in NT-proBNP (pmol/L); MD −157.47 (95% CI −327.64 to 12.70), p=0.07 ([figure 2](#F2){ref-type="fig"}). Notably, the large size of the improvement was due to the inclusion of one study[@R45] ([figure 4](#F4){ref-type="fig"}). One[@R42] additional study, in patients with HFpEF, not pooled, failed to demonstrate any significant change ([table 2](#T2){ref-type="table"}).

![Sensitivity analysis NT-proBNP (non-conventional training) with study removed. NT-proBNP, amino (N) portion of BNP.](openhrt-2018-000819f04){#F4}

### Brain natriuretic peptide {#s3d5}

Twenty-two studies reported on BNP. Two[@R32] studies contained an overlap of some participants; to avoid duplication of data, these studies are represented as one dataset in the meta-analysis.

### Meta-analysis {#s3d6}

Overall, exercise demonstrated a statistically significant improvement in BNP (pmol/L); MD −15.02 (95% CI −25.06 to −4.99), p=0.003 ([figure 5](#F5){ref-type="fig"}).

![Change (MD) in BNP (pmol/L) exercise versus control. For conversion to pg/mL=pmol/L divided by 0.289. AIT, aerobic interval training; BNP, brain natriuretic peptide; LIPRT, low-intensity inspiratory training and peripheral resistance training; MCT, moderate continuous training; MD, mean difference MIPRT, moderate-intensity inspiratory and peripheral resistance training.](openhrt-2018-000819f05){#F5}

### Conventional training {#s3d7}

Pooled data from 11 studies[@R32] (12 intervention groups, 268 exercise participants and 192 controls) demonstrated a statistically significant improvement in BNP (pmol/L) in favour of exercise; MD −17.17 (95% CI −29.56 to −4.78), p=0.007([figure 5](#F5){ref-type="fig"}). Sensitivity analyses using the leave-one-out approach revealed that the study by Gary *et al* [@R59] impacted the size of the result, with an increase in MD and statistical significance with removal of this study ([figure 6](#F6){ref-type="fig"}).

![Sensitivity analysis BNP (conventional training) with study removed. AIT, aerobic interval training; BNP, brain natriuretic peptide; MCT, moderate continuous training.](openhrt-2018-000819f06){#F6}

An additional five[@R22] studies using conventional training ([table 2](#T2){ref-type="table"}) reported on BNP concentrations, but were not pooled due to differences in data reporting. Two[@R22] studies reported data as median (IQR), two[@R39] studies were in participants with HFpEF and one[@R65] study did not provide post-data but noted no change. Of the five studies, two[@R22] reported decreases post-training in exercise participants with no change in controls. The two[@R39] studies with HFpEF patents failed to find any change.

### Non-conventional training {#s3d8}

Pooled data from 4 studies[@R66] (5 intervention groups, 86 exercise participants and 59 controls) failed to demonstrate a statistically significant improvement in BNP (pmol/L) exercise versus control; MD −9.92 (95% CI −28.03 to −8.20), p=0.28 ([figure 5](#F5){ref-type="fig"}). Sensitivity analysis indicated that the study by Kawauchi *et al* [@R68] affected the magnitude of the result ([figure 7](#F7){ref-type="fig"}). Sensitivity analyses conducted for different correlation coefficients for SD imputation did not result in any significant variance in overall results. Two[@R41] additional studies, using non-conventional training, were not pooled. One[@R70] reported data as median (IQR), and one[@R41] was in patients with HFpEF, and both failed to demonstrate any significant change ([table 2](#T2){ref-type="table"}).

![Sensitivity analysis BNP (non-conventional training) with study removed. BNP, brain natriuretic peptide; LIPRT, low-intensity inspiratory training and peripheral resistance training; MIPRT, moderate-intensity inspiratory and peripheral resistance training.](openhrt-2018-000819f07){#F7}

### Cardiac troponin {#s3d9}

Only a substudy of the HF ACTION trial reported on the effect of exercise training on cTnT levels compared with control participants, with no decreases in detectable levels of cTnT found in a cohort of participants from the trial.[@R53]

### Galectin-3 {#s3d10}

Two studies compared Gal-3 in exercising and control participants. However, differences in data reporting did not allow for data pooling. Billebeau *et al* [@R22] observed a statistically significant (p\<0.001) median decrease of 6.3% in the exercise group (n=107) with no change in control patients. While Fernandes-Silva *et al* [@R23] reported no statistically significant difference in the mean change between exercise and control groups (p=0.69).

### Soluble ST2 {#s3d11}

One study reported predata and postdata in regard to the effect of exercise training on sST2 levels. A statistically significant (p=0.035) median decrease of 7.4% was observed post-training (n=97) by Billebeau *et al*,[@R22] with no change in controls.

### MR-proANP {#s3d12}

Two studies reported on postintervention MR-proANP concentrations. Billebeau *et al* [@R22] observed a statistically significant (p\<0.001) median decrease of 16% post-training (n=105), with no changes in control participants. In contrast, the post hoc analysis of the Ex-DHF pilot trial by Trippel *et al* [@R31] noted no significant treatment effect in patients with HFpEF.

### Mid-regional adrenomedullin {#s3d13}

Two studies reported on postintervention MR-proADM concentrations. Billebeau *et al* [@R22] observed a statistically significant (p=0.001) 6.4% median decrease in MR-proADM (n=103), with no changes in control participants. In contrast, Trippel *et al* [@R31] noted no significant treatment effect in patients with HFpEF.

### Copeptin {#s3d14}

One study by Trippel *et al* [@R31] reported on CT-proAVP levels and failed to find any statistically significant change post-training or compared with the control group in patients with HFpEF.

Study quality and reporting {#s3e}
---------------------------

A median TESTEX score of 8.5 out of 15 was obtained (range 6--12) (online [supplementary table S6](#SP1){ref-type="supplementary-material"}). Details of randomisation procedures, activity monitoring of control groups, adjustment of relative exercise intensity and provision of adequate details to calculate exercise energy expenditure were frequently lacking.

Heterogeneity and publication bias {#s3f}
----------------------------------

Meta-analyses indicated a moderate level of heterogeneity. Visual inspection of the funnel plot showed slight asymmetry (online [supplementary figures 1A,B](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This systematic review and meta-analysis compiled evidence from a large volume of studies assessing the effect of exercise therapy on established and a selected number of emerging biomarkers in patients with HF. Different to previous analyses, both conventional and non-conventional modes of training were examined. When analysed separately, conventional training demonstrated a statistically significant improvement in NT-proBNP and BNP, while pooled analyses of non-conventional training failed to demonstrate any significance. While BNP and NT-proBNP are raised across the HF spectrum, as levels may be lower in HFpEF, and in some instances close to normal, we excluded studies from pooled analyses that only included patients with HFpEF. However, it is highly likely that a number of other studies included in the analyses with mean ejection fractions \>40% would have also included patients with HFpEF, and it is possible that this could be reflected in the variability of the results.

The favourable result demonstrated in pooled analyses of conventional training is consistent with previous reviews[@R24] and a 2011 IPD meta-analysis.[@R25] However, in contrast to our pooled results, of studies unable to be pooled, only two of seven studies for BNP, and two of the seven studies for NT-proBNP, indicated any significant change post-training or compared with controls. Furthermore, one of these studies was a sub-analysis of a large cohort from the HF ACTION trial, which found that levels of plasma NT-proBNP did not significantly improve after 3 months of AT,[@R53] clearly contrasting with our result and previous analyses.[@R24] However, adherence and participant crossover issues may have confounded the results of the HF ACTION trial. It is also possible that a longer intervention duration may have resulted in significant changes, as seen after 9 months by Passino *et al*,[@R32] although Sandri *et al* [@R51] demonstrated significant decreases after only 4 weeks of endurance training.

Emerging biomarkers {#s4a}
-------------------

While BNP/NT-proBNP remains the gold standard HF biomarkers, with proven prognostic value, there are limitations. Age, gender, arrhythmias, obesity, renal function and comorbidities[@R10] may all affect concentrations; hence, biomarkers less affected by these issues can provide valuable information. Furthermore, as biomarkers of myocardial stretch, BNP/NT-proBNP is only reflective of one pathophysiological pathway involved in HF; hence, biomarkers reflecting other pathways may provide new and valuable information and complement BNP/NT-proBNP. Both Gal-3 and sST2 have been studied as emerging biomarkers in HF, and now have a Class IIB recommendation for risk stratification by the American College of Cardiology/American Heart Association (ACC/AHA) (2013) guideline for HF management.[@R7] Gal-3, a β-galactoside-binding lectin, plays a dominant role in inflammation, fibrosis and cardiac remodelling.[@R10] sST2, a member of the interleukin (IL)-1 receptor family and defined as a ligand for IL-33, is considered a cardiovascular stress protein, associated with fibrosis, cardiac and vascular remodelling and inflammation.[@R72] Initial evidence also indicates that other novel biomarkers, such as CT-proAVP[@R20] and MR-proADM,[@R75] both biomarkers of neurohormonal activation, also have prognostic value in HF.

Current evidence does not allow for any conclusion as to the effect of exercise training on emerging biomarkers. However, the recent studies of Fernandes-Silva *et al* [@R23] and Billebeau *et al* [@R22] provide an interesting and perhaps promising platform on which future research can expand. Billebeau *et al*,[@R22] in a non-randomised trial, observed a significant decrease in BNP, MR-proANP, MR-proADM, Gal-3 and sST2 in exercise training participants with no change in controls. Analysis according to change in VO~2peak~ demonstrated that patients with an increase in VO~2peak~ ≥14.5% (based on the median increase) experienced a significant decrease in Gal-3, sST2, MR-proADM and MR-proANP compared with no significant biomarker change in participants with change in VO~2peak~ \<14.5%.[@R22] Furthermore, given that BNP improved regardless of the change in VO~2peak~, they concluded that the addition of the newer biomarkers improved the clinical follow-up of rehabilitation.[@R22] Overall, their results demonstrated that exercise training improves neurohormonal, inflammatory and fibrotic processes.[@R22] Fernandes-Silva *et al* [@R23] observed no significant difference between exercise and control patients for change in Gal-3 or the proinflammatory markers (IL-6 and tumour necrosis factor-α); however, VO~2peak~ significantly improved in participants with low baseline Gal-3 levels, compared with patients with high levels, with similar findings for the proinflammatory markers. These results suggesting biomarkers may predict a patient's response to training.[@R23] Interestingly, in a substudy of the HF ACTION trial, higher baseline ST2 levels were associated with a greater improvement in VO~2peak~ at 3 months.[@R76]

Exercise capacity {#s4b}
-----------------

Reduced exercise capacity is a major hallmark of HF, and NT-proBNP is a strong predictor of VO~2peak~.[@R77] Changes in BNP and NT-proBNP have been correlated with changes in VO~2peak~ and suggested therefore as a possible surrogate for evaluating training responses.[@R25] Only a minimal number of studies included in the review reported associations between change in peak VO~2peak~ and biomarkers. Ahmad *et al* [@R53] did however observe that in patients in whom NT-proBNP levels decreased, there was an increase in VO~2peak~, despite finding no significant change in NT-proBNP. While Passino *et al* [@R32] observed that changes in VO~2peak~ correlated significantly with decreases in NT-proBNP and BNP. Recently, Billebeau *et al* found that of all the biomarkers they tested, for predicting change in exercise capacity, MR-proADM best correlated with VO~2peak~.[@R22] Given that adrenomedullin originates not only from the heart but also from multiple organs, tissues and blood vessels[@R78] and that the mechanisms associated with improved exercise capacity in HF involve cardiac, vascular and skeletal muscle adaptations,[@R79] a relationship between MR-proADM and improved exercise capacity makes sense.

Phenotype {#s4c}
---------

Levels of BNP and NT-proBNP are elevated irrespective of ejection fraction; although they are generally lower in HFpEF compared with heart failure with reduced ejection fraction (HFrEF).[@R80] Patients also present with elevated levels of a number of other biomarkers reflective of different pathophysiological pathways. Currently, there are limited data on the role of exercise training and biomarkers in HFpEF, and none of the HFpEF studies included in the review reported any significant changes in the biomarkers. Furthermore, it is likely that there exist different biomarker profiles for HFrEF and HFpEF.[@R83] Moving forward, these different biomarker profiles may provide valuable information for treatment strategies, including exercise.

Exercise prescription {#s4d}
---------------------

While moderate continuous training (MCT) has been the cornerstone of conventional HF training, over the past decade, the interest in high-intensity interval training (HIIT) has grown.[@R85] Two studies included in the review that specifically incorporated HIIT and MCT groups for comparative purposes observed significant improvements in BNP[@R57] and NT-proBNP[@R47] from HIIT, with no significant change from MCT. However, this is in contrast to the recent results of the larger, multicentre SMARTEX HF study, which failed to demonstrate any significant difference between HIIT and MCT after 12 weeks.[@R86] However, for comparisons, difficulty arises in regard to actual training intensities attained, and in SMARTEX, both actual HIIT and MCT intensities attained may have impacted the results, with patients training at lower and higher intensities than prescribed.[@R86]

To date, the majority of HF training studies have used conventional modes of training; however, not all patients can or are willing to participate in these activities. Women, for example, may be more likely to attend mind--body interventions, such as Tai Chi and Yoga, for cardiac rehabilitation purposes.[@R87] Furthermore, both FES and IMT offer alternative modes of physical therapy, particularly in patients unable to participate in more conventional modalities. Individually, the included studies investigating FES and IMT failed to demonstrate any significant change in BNP or NT-proBNP compared with control groups. However, the combination of these non-conventional modes with conventional training may provide possible synergistic effects,[@R89] as demonstrated by Caminiti *et al* [@R90] with combined Tai Chi/endurance training and Adamopoulos *et al* [@R89] with combined IMT/AT. Furthermore, other modes of non-conventional exercise therapy, such as weight-supported[@R91] and robot-assisted[@R92] exercise training, have demonstrated improvements in BNP and NT-proBNP in patients with HF and may be beneficial in some subgroups.

Clinical significance and future research {#s4e}
-----------------------------------------

Biomarkers are used in HF clinical trials for a number of reasons,[@R10] including establishment of inclusion criteria, outcome measures, explaining therapeutic efficacy and as a target for therapy.[@R93] Biomarkers and biomarker panels may aid in identifying subgroups of patients with HF who may have a more favourable response to exercise therapy, distinguishing responders and non-responders[@R21] in terms of specified outcomes including functional and long-term outcomes. Different biomarkers may provide further insight into the downstream molecular mechanisms associated with improvements from exercise training.[@R21] It could be possible that different biomarker profiles respond differently to different intervention characteristics, such as intensity, perhaps allowing further tailoring of the exercise to the individual. Furthermore, biomarkers, with their prognostic utility, may provide useful postintervention information, indicating improvements when other favourable outcomes may be absent. It remains premature to draw too many conclusions about the relationship between changes in emerging biomarkers and exercise training, and the utility of these biomarkers in HF is yet to be fully established, but it presents as an interesting and important area for future research.

Future research also needs to consider the clinical interpretation of changes in biomarkers given their biological variation.[@R94] While NT-proBNP is considered to have high biological variation, the newer markers of sST2 and Gal-3 demonstrate a lower variation and therefore add value to their use.[@R94] However, from an individual perspective in interpreting clinically meaningful changes in biomarkers, it is suggested that reference change values which indicate the percentage change necessary within an individual, reflective of a true change as opposed to biological variation, be used.[@R94]

Strengths and limitations in the systematic review and meta-analysis {#s4f}
--------------------------------------------------------------------

To our knowledge, this is the first meta-analysis of BNP and NT-proBNP to include training studies beyond the conventional AT and RT modalities and the first review to consider exercise therapy and emerging biomarkers in HF. We aimed to provide a meta-analysis of studies reporting on a selected number of established and emerging biomarkers. However, as biomarker distributions can be skewed, study data may often be presented as median (IQR) or median (range), which precludes it from inclusion in meta-analyses. Valuable information may be ignored if a number of studies are excluded; therefore, on initial review and identification of a number of studies that had examined biomarkers and reported data as median or provided a descriptive result, we felt that the inclusion of these studies would enhance the value of the review and analysis. Therefore, we included results of studies reporting data that were considered inappropriate for pooling and only provided a descriptive analysis of these studies.

Studies in which biomarkers were assessed as secondary outcomes may not have been adequately powered to detect significant differences in biomarkers. Furthermore, the studies included in the review reported a wide range of intervention durations, training frequency, session times and intensity. In regard to data pooling, we measured the difference between preintervention and postintervention means; however, in cases where exact p values within groups or 95% CI were not available, we imputed the SD, and hence statistical analysis depended on extrapolated data. However, our imputation was conservative, and sensitivity analyses were conducted for different correlation coefficients. Abstracts and trials not reported in English were excluded and could have led to publication bias.

Conclusion {#s5}
==========

Pooled data of conventional training modalities indicated a favourable effect on the established HF biomarkers, NT-proBNP and BNP, contrasting with information from a number of non-pooled studies. Limited evidence exists in regard to exercise training and emerging biomarkers. Given the complex pathways involved in the onset and progression of HF, more research is required to establish exactly how established and emerging biomarkers can be used in exercise training in this population. The use of multiple biomarkers is an area of active research in HF, and future studies using biomarker panels may prove beneficial in guiding non-pharmacological therapy such as exercise by facilitating a more precise approach to exercise for subgroups of patients.
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